Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Vorinostat with Chemotherapy for Relapsed/Refractory ALL or LL
NCT00882206Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2009
- Primary completion
- Jan 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of decitabine and vorinostat in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Masonic Cancer Center. Started Apr 2009; status: terminated.
02
Drugs
decitabinevorinostat
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00882206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882206.